

研究成果の刊行に関する一覧表

雑誌

1. Wannigama DL, Hurst C, Monk PN, Hartel G, Ditcham WGF, Hongsing P, Phattharapornjaroen P, Ounjai P, Torvorapanit P, Jutivorakool K, Luk-In S, Nilgate S, Rirerm U, Tanasatitchai C, Miyanaga K, Cui L, Ragupathi NKD, Rad SMAH, Khatib A, Storer RJ, Ishikawa H, Amarasiri M, Charuluxananan S, Leelahavanichkul A, Kanjanabuch T, Higgins PG, Davies JC, Stick SM, Kicic A, Chatsuwan T, Shibuya K, Abe S. *tesG* expression as a potential clinical biomarker for chronic *Pseudomonas aeruginosa* pulmonary biofilm infections. *BMC medicine* 23, 191, 2025.
2. Shein AMS, Wannigama DL, Hurst C, Monk PN, Amarasiri M, Wongsurawat T, Jenjaroen pun P, Phattharapornjaroen P, Ditcham WGF, Ounjai P, Thammakorn Saethang T, Chantar avisoot N, Badavath VN, Luk-in S, Nilgate S, Rirerm U, Srisakul S, Kueakulpattana N, Laowansiri M, Rad SMAH, Wacharapluesadee S, Rodpan A, Ngamwongsatit N, Thammahong A, Ishikawa H, Storer RJ, Leelahavanichkul A, Ragupathi NKD, Classen AY, Kanjanabuch T, Pletzer D, Miyanaga K, Cui L, Hamamoto H, Higgins PG, Kicic A, Chatsuwan T, Hongsing P, Abe S. Phage cocktail amikacin combination as a potential therapy for bacteremia associated with carbapenemase producing colistin resistant *Klebsiella pneumoniae*. *Sci Rep.* 14, 28992, 2024.
3. Abe S, Wannigama DL. Quick sequential organ failure assessment (qSOFA) and performance status scoring systems as prognostic predictors in pneumococcal community-acquired pneumonia. *Cureus.* 16, e73201, 2024.
4. Abe S, Wannigama DL, Suzuki Y, Akaneya D, Igarashi J, Suto M, Moriya K, Ishizawa D, Okuma Y, Hongsing P, Hurst C, Saethang T, Higgins PG, Stick SM, Kicic A. Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series. *New Microbes New Infect.* 62, 101522, 2024.
5. Wannigama DL, Amarasiri M, Phattharapornjaroen P, Hurst C, Modchang C, Besa JJV, Miyanaga K, Cui L, Fernandez S, Huang AT, Ounjai P; Pathogen Hunters Research Team, Singer AC, Naveen Kumar Devanga Ragupathi NKD, Furukawa T, Sei K, Nanbo A,

Leelahavanichkul A, Kanjanabuch T, Chatsuwan T, Higgins PG, Sano D, Kicic A, Rockstroh JK, Siow R, Trowsdale S, Hongsing P, Khatib A, Shibuya K, Abe S. Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south. *Lancet Infect Dis.* 24, e610, 2024.

6. Wannigama DL, Amarasiri M, Phattharapornjaroen P, Hurst C, Modchang C, Chadsuthi S, Anupong S, Miyanaga K, Cui L, Fernandez S, Huang AT, Ounjai P, Singer AC, Ragupathi NKD, Sano D, Furukawa T, Sei K, Leelahavanichkul A, Kanjanabuch T, Chatsuwan T, Higgins PG, Nanbo A, Kicic A, Siow R, Trowsdale S, Hongsing P, Khatib A, Shibuya K, Abe S, Ishikawa H; Pathogen Hunters Research Team. Increased faecal shedding in SARS-CoV-2 variants BA.2.86 and JN.1. *Lancet Infect Dis.* 24, e348, 2024.

7. Wannigama DL, Hurst C, Phattharapornjaroen P, Hongsing P, Sirichumroonwit N, Chanpiwat K, Rad S M AH, Storer RJ, Ounjai P, Kanthawee P, Ngamwongsatit N, Kupwiwat R, Kupwiwat C, Brimson JM, Devanga Ragupathi NK, Charuluxananan S, Leelahavanichkul A, Kanjanabuch T, Higgins PG, Badavath VN, Amarasiri M, Verhasselt V, Kicic A, Chatsuwan T, Pirzada K, Jalali F, Reiersen AM, Abe S, Ishikawa H; COVID-EarlyMed Trial Team. Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial. *eClinical Medicine.* 70, 102517, 2024.

8. Wannigama DL, Amarasiri M, Phattharapornjaroen P, Hurst C, Modchang C, Chadsuthi S, Anupong S, Miyanaga K, Cui L, Werawatte WKCP, Rad SMAH, Fernandez S, Huang AT, Vatanaprasan P, Saethang T, Luk-In S, Storer RJ, Ounjai P, Tacharoenmuang R, Ragupathi NKD, Kanthawee P, Cynthia B, Besa JJV, Leelahavanichkul A, Kanjanabuch T, Higgins PG, Nanbo A, Kicic A, Singer AC, Chatsuwan T, Trowsdale S, Furukawa T, Sei K, Sano D, Ishikawa H, Shibuya K, Khatib A, Abe S, Hongsing P. Wastewater-based epidemiological surveillance of SARS-CoV-2 new variants BA.2.86 and offspring JN.1 in South and Southeast Asia. *J Travel Med,* 31, taee040, 2024.

9. Anupong S, Chadsuthi S, Hongsing P, Hurst C, Phattharapornjaroen P, Ali Hosseini RSM, Fernandez S, Huang AT, Vatanaprasan P, Saethang T, Luk-In S, Storer RJ, Ounjai P, Ragupathi NKD, Kanthawee P, Ngamwongsatit N, Badavath VN, Thuptimrang W, Leelahavanichkul A, Kanjanabuch T, Miyanaga K, Cui L, Nanbo A, Shibuya K, Kupwiwat R, Sano D, Furukawa T, Sei K, Higgins PG, Kicic A, Singer AC, Chatsuwan T, Trowsdale S, Abe S, Ishikawa H, Amarasiri M, Modchang C, Wannigama DL. Exploring indoor and

outdoor dust as a potential tool for detection and monitoring of COVID-19 transmission. *iScience*. 27, 109043. 2024.

10. Shinkai M, Ota S, Ishikawa N, Tanimoto T, Suzuki H, Abe S, Vandendijck Y, Nakayama Y, Murata Y. Burden of respiratory syncytial virus, human metapneumovirus and influenza virus infections in Japanese adults in the Hospitalized Acute Respiratory Tract Infection study. *Respir Investig*. 62, 717, 2024.

11. Tamura K, Shimbashi R, Kasamatsu A, Chang B, Gotoh K, Tanabe Y, Kuronuma K, Oshima K, Maruyama T, Nakamatsu M, Abe S, Kasahara K, Nishi J, Arakawa Y, Kinjo Y, Suzuki M, Akeda Y, Oishi K; Adult IPD Study Group. Unveiling the role of preceding seasonal influenza in the development of bacteremic pneumococcal pneumonia in older adults before the COVID-19 pandemic in Japan. *Int J Infect Dis*. 2024 Jun;143:107024. doi: 10.1016/j.ijid.2024.107024. Epub 2024 Apr 5. PMID: 38582146.

12. 藤倉 裕之, 笠原 敬. 肺炎球菌感染症の最近の動向 内科領域. *臨床と微生物* 51(5) : 432-438.

13. Hayashizaki K, Kamii Y, Kinjo Y. Glycolipid antigen recognition by invariant natural killer T cells and its role in homeostasis and antimicrobial responses. *Front Immunol* 2024; 15: 1402412.

14. Abe M, Kinjo Y, Koshikawa T, Miyazaki Y. Basic Research on *Candida* Species. *Med Mycol J* 2024; 65(3): 67-74.

15. Gotoh K, and Kakimoto K. Transition of yellow fever immunization environment in Japan. *J Infect Chemother*. 2025 Mar 21:102685. doi:10.1016/j.jiac.2025.102685.

16. Miya Andou, Masaki Tominaga, Ryuta Nishikomori, Kenji Gotoh, Nobukazu Komatsu Masanobu Matsuoka, Tomotaka Kawayama and Tomoaki Hoshino STAT1 Mutations in Chronic Mucocutaneous Candidiasis Diagnosed in an Adult. *Intern Med* 63: 1269-1271, 2024

17. Tanamachi C, Iwahashi J, Togo A, Ohta K, Miura M, Sakamoto T, Gotoh K, Horita R, Kamei K, and Watanabe H. Molecular analysis for potential hospital-acquired infection caused by *Aspergillus tubingensis* through the environment. *Kurume Med J*. 2024 Jan 16. doi:10.2739/10.2739/

18. 山口璃紗、三宅 淳、田代尚崇、屋宮清仁、後藤憲志、大園秀一、山下裕史朗「小児科病棟で1か月半の間に発生した *Gordonia* 属菌菌血症2症例の検討」小児感染免疫 36: 271-276, 2024.
19. 成人肺炎診療ガイドライン 2024. P28-48 一般社団法人日本呼吸器学会
20. Chan KF, Ma TF, IpMS, et al. Invasive pneumococcal disease, pneumococcal pneumonia and all-cause pneumonia in Hong Kong during the COVID-19 pandemic compared with the preceding 5 years: a retrospective observational study. *BMJ Open* 2021;11(10):e055575.
21. Brueggemann AB, Jansen van Rensburg MJ, Shaw D, et al. Changes in the incidence of invasive disease due to *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitis* during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. *Lancet Digit Health* 2021;3(6):e360-e370.
22. Prasad N, Rhodes J, Deng L, McCarthy N, Moline HL, et al. Changes in the Incidence of Invasive Bacterial Disease During the COVID-19 Pandemic in the United States, 2014-2020. *J Infect Dis.* 2023 Feb 1:jiad028.
23. Khongyot T, Moriyasu T. Invasive Pneumococcal Disease diminish during the onset of COVID-19 in Japan between 2019 and 2022. *Int J Infect Dis.* 2022 Sep;122:307-309.
24. Van Groningen KM, Dao BL, Gounder P. Declines in invasive pneumococcal disease (IPD) during the COVID-19 pandemic in Los Angeles county. *J Infect.* 2022 Aug;85(2):174-211. doi: 10.1016/j.jinf.2022.05.002. Epub 2022 May 9. PMID: 35550382; PMCID: PMC9081043.
25. 第58回厚生科学審議会予防接種・ワクチン分科会 予防接種基本方針部会資料 <https://www.mhlw.go.jp/content/10900000/001225284.pdf>
26. 国立感染症研究所, A群溶血性レンサ球菌による劇症型溶血性レンサ球菌感染症の50歳未満を中心とした報告数の増加について. *IASR Vol. 45* p29-31
27. Takahashi H, Ohama Y, Horiba K, Fukusumi M, Sunagawa T, Ariyoshi T, Koide M,

Shimuta K, Saito R, Akeda Y. Emergence of high-level penicillin-resistant *Neisseria meningitidis* harboring ROB-1-type β -lactamase gene. *Journal of Infection and Chemotherapy*, 102679., 2025.

28. Shimuta K, Ohama Y, Ito S, Hoshina S, Takahashi H, Igawa G, Dorin Yamamoto M, Akeda Y, Ohnishi M. Emergence of ceftriaxone-resistant *Neisseria gonorrhoeae* through horizontal gene transfer among *Neisseria* spp. *Journal of Infectious Diseases*. jiaf008, 2025.

29. T Kobayashi M, Kamiya H, Fukusumi M, Takahashi H, Akeda Y, Suzuki M, Sunagawa T. Euro Surveillance, Epidemiology of invasive meningococcal disease, Japan, 2013 to 2023. 2400136, 2024.

30. Ishikawa K, Takahashi H, Akeda Y, Mori N. Emerging Meningococcal B Meningitis in Japan: A Case Report of a 50-Year-Old Japanese Man with Diabetes. *American Journal of Case Report*. e943973, 2024.

31. Yokoyama Y, Ichiki T, Yamakawa T, Tsuji Y, Kuronuma K, Takahashi S, Narimatsu E, Katanuma A, Nakase H. Gut microbiota and metabolites in patients with COVID-19 are altered by the type of SARS-CoV-2 variant. *Front Microbiol*. 2024 Mar 5;15:1358530. doi: 10.3389/fmicb.2024.1358530. PMID: 38505560; PMCID: PMC10948395.

32. Ngo LT, Rekowski MJ, Koestler DC, Yorozuya T, Saito A, Azeem I, Harrison A, Demoruelle MK, Boomer J, England BR, Wolters P, Molyneaux PL, Castro M, Lee JS, Solomon JJ, Karonuma K, Washburn MP, Matson SM. Proteomic profiling of bronchoalveolar lavage fluid uncovers protein clusters linked to survival in idiopathic forms of interstitial lung disease. *ERJ Open Res*. 2024 Dec 16;10(6):00192-2024. doi: 10.1183/23120541.00192-2024. PMID: 39687393; PMCID: PMC11647942.

33. Kuronuma K. Importance of vaccines against respiratory infections in adults. *Respir Investig*. 2024 Nov;62(6):1202-1203. doi: 10.1016/j.resinv.2024.09.006. Epub 2024 Oct 23. PMID: 39447447.

34. 中江 舞美, 藤谷 好弘, 黒沼 幸治, 小林 亮, 佐藤 勇樹, 葦澤 慎也, 村井 良精, 高橋 聡. COVID-19 と診断され入院後の確認検査で偽陽性と判定された8事例に関する検討. *環境感染誌* 2024; 39: 4

35. 黒沼幸治. 肺炎マイコプラズマ感染症と免疫・アレルギー性肺疾患の関係. 臨床検査, 68 ; 6, 748-752, 2024.
36. 黒沼幸治. 特集：新型コロナを経て見直す 隔離予防策—手指衛生と接触予防策■病原体別接触予防策の実践③ノロウイルス、ロタウイルス, 感染対策 ICT ジャーナル, 19 ; 3, 212-216, 2024.
37. Katayama Y, Morita M, Chang B, Katagiri D, Ishikane M, Yamada G, Mezaki K, Kurokawa M, Takano H, Akeda Y. Identification and characterization of a novel α -haemolytic streptococci, *Streptococcus parapneumoniae* sp. nov., which caused bacteremia with pyelonephritis. International Journal of Medical Microbiology. 315, 151625, 2024.
38. Kajihara T, Yahara K, Kamigaki T, Hirabayashi A, Hosaka Y, Kitamura N, Shimbashi R, Suzuki M, Sugai M, Shibayama K. Effects of coronavirus disease 2019 on the spread of respiratory-transmitted human-to-human bacteria. J Infect; 89(2):106201:2024.
39. Nakashio M, Nikaido R, Nishi J, Kasai M, Morisawa T. Haemophilus influenzae type f meningitis with an intraventricular abscess. Cureus, 17, e79187, 2025.
40. Garcia Quesada M, et al. The PSERENADE Team. Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccine: a global surveillance analysis. Lancet Infect Dis, 25, 445, 2025.
41. Bennet JC, Oishi K, et al. Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal diseases in all ages: The PSERENADE project. Lancet Infect Dis, 25, 457, 2025.
42. Yang Y, Oishi K, et al. Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project. J Infect, 90, 106426, 2025.
43. 大石和徳. 肺炎球菌ワクチン. 日本内科学会雑誌, 113, 2058, 2024.

44. 大石和徳. 肺炎球菌ワクチン：高齢者. 臨床とウイルス, 52, 222, 2024.
45. Issei Seike, Kengo Oshima, Hiroaki Baba, Hajime Kanamori, Tetsuji Aoyagi, Undiagnosed Perihepatic Abscess Revealed at Autopsy of a Patient With COVID-19 Undergoing Prolonged Extracorporeal Membrane Oxygenation (ECMO) Therapy. Cureus, 15, e58338, 2024.
46. Gong W, Ono M, Yamaguchi M, Motooka D, Hirose Y, Higashi K, Kobayashi M, Ikeda E, Sumitomo T, Okuno R, Yamaguchi T, Kawahara R, Otsuka H, Nakanishi N, Kazawa Y, Nakagawa C, Yamaguchi R, Sakai H, Matsumoto Y, Ikebe T, Kawabata S. A comprehensive analysis of antimicrobial resistance of clinical emm89 *Streptococcus pyogenes* in Japan. JAC Antimicrob Resist. 2025 Feb 19;7(1):dlaf017. doi: 10.1093/jacamr/dlaf017.
47. Koizumi N, Shikama Y, Ikebe T, Nagafuchi H, Imagawa T. Toxic shock syndrome caused by *Streptococcus dysgalactiae* subspecies *equisimilis*: A report of a rare pediatric case. Cureus. 2025 Feb 5;17(2):e78573. doi: 10.7759/cureus.78573.
48. Ogawa K, Kamiyama J, Ikebe T, Taguchi S, Kiyota K. Streptococcal toxic shock syndrome caused by a *Streptococcus pyogenes* emm22 genotype with a CsrS Mutation: a case report. Jpn J Infect Dis. 2024 Nov 21;77(6):348-352. doi: 10.7883/yoken.JJID.2023.332.
49. 侵襲性髄膜炎菌感染症発生時 対応ガイドライン〔第二版〕 <https://id-info.jihs.go.jp/other/060/index.html>